On September 12, Ge Longhui Pharmaceutical (300149.SZ) held a performance briefing on September 12, 2024. “I heard that the company's ADC Global Innovation Center has already been launched. What is the specific situation?” The company said that Wisdom Pharmaceuticals' ADC Global Innovation Center covers antibody development, pharmacochemistry, bioconjugation and characterization, in vivo pharmacodynamics, pharmacokinetics and early toxicology research starting with drug targets. It can provide integrated ADC drug development services from antibody development to IND application. It has cooperated with many well-known pharmaceutical companies at home and abroad to complete hundreds of early ADC R&D projects and assist customers to apply for multiple patents, involving 20+ different targets to synthesize 1,000+ innovative linker-pay-load compounds. In the current cooperative ADC project, 30+ ADC molecules have entered the clinical or PCC research stage.